An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2017
At a glance
- Drugs MDNA 55 (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Medicenna Therapeutics
- 16 Nov 2017 According to a Medicenna Therapeutics media release, additional clinical data from the first 15 patients treated to date in this trial were presented at the 22nd Annual Meeting of the Society of Neuro-Oncology (SNO).
- 14 Nov 2017 According to a Medicenna Therapeutics media release, results were presented Cancer Prevention and Research Conference held from November 13-14, 2017 in Austin.
- 14 Nov 2017 Results published in the Medicenna Therapeutics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History